Enzo Biochem Inc

NYSE ENZ

Download Data

Enzo Biochem Inc Price to Earnings Ratio (P/E) on June 03, 2024: -2.16

Enzo Biochem Inc Price to Earnings Ratio (P/E) is -2.16 on June 03, 2024, a 7.48% change year over year. The price to earnings ratio (P/E ratio) compares the market price per share of a company's stock to its earnings per share (EPS). It is calculated by dividing the market capitalization by the net income, divided by the number of outstanding shares. This ratio provides insights into the market's valuation of a company's earnings. A higher P/E ratio indicates that investors are willing to pay a higher price for each unit of earnings, suggesting higher market expectations for future earnings growth.
  • Enzo Biochem Inc 52-week high Price to Earnings Ratio (P/E) is -1.39 on July 17, 2023, which is 35.56% above the current Price to Earnings Ratio (P/E).
  • Enzo Biochem Inc 52-week low Price to Earnings Ratio (P/E) is -12.10 on January 02, 2024, which is -459.60% below the current Price to Earnings Ratio (P/E).
  • Enzo Biochem Inc average Price to Earnings Ratio (P/E) for the last 52 weeks is -4.02.
NYSE: ENZ

Enzo Biochem Inc

CEO Mr. Hamid Erfanian
IPO Date June 12, 1980
Location United States
Headquarters 81 Executive Blvd., Farmingdale, NY, United States, 11735
Employees 179
Sector Healthcare
Industry Diagnostics & research
Description

Enzo Biochem, Inc. develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. It also provides AMPIVIEW in situ hybridization probes for enhanced detection of low expressed targets useful in the growing spatial biology space; reagents and assays for cell and gene therapy research and development; POLYVIEW PLUS Enhanced Immunohistochemistry platform, offers solutions within the area of anatomical pathology through optimized assays; Enhanced Immunoassays, pushing sensitivity to expand immunoassay applications for basic research, bioprocess, and diagnostics; AMPIPROBE, a nucleic acid amplification platform; and Axxora.com, a proven distribution platform for original manufacturers of innovative research reagents. The company's proprietary products and technologies in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry, and small molecule chemistry. It markets its products and services through its direct sales force and a network of distributors. The company was incorporated in 1976 and is headquartered in Farmingdale, New York.

Similar companies

FONR

Fonar Corporation

NA

NA

SERA

Sera Prognostics Inc

NA

NA

OLK

Olink Holding AB ADR

NA

NA

DRIO

DarioHealth Corp

NA

NA

XGN

Exagen Inc

NA

NA

BDSX

Biodesix Inc

NA

NA

StockViz Staff

September 19, 2024

Any question? Send us an email